HeartSciences (HSCS) – Investment Analysts’ Recent Ratings Changes

HeartSciences (NASDAQ: HSCS) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – HeartSciences had its price target raised by analysts at Ascendiant Capital Markets from $9.00 to $9.20. They now have a “buy” rating on the stock.
• 12/15/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – HeartSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.